Chemoprophylaxis for HIV Prevention in Men.

Trial Profile

Chemoprophylaxis for HIV Prevention in Men.

Completed
Phase of Trial: Phase III

Latest Information Update: 03 Feb 2018

At a glance

  • Drugs Emtricitabine/tenofovir disoproxil fumarate (Primary)
  • Indications Herpes simplex virus type 2 infections; HIV infections
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms iPrEX
  • Most Recent Events

    • 03 Feb 2018 Results (n=498) assessing effects of TDF/FTC on lipids and body composition in participants in a blinded placebo controlled iPrEP trial, were published in the Clinical Infectious Diseases.
    • 10 Jun 2017 Biomarkers information updated
    • 29 Aug 2016 Results of this and other four studies published in the Antimicrobial Agents and Chemotherapy (2016).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top